These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 33445855)
81. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Jovanovic JV; Score J; Waghorn K; Cilloni D; Gottardi E; Metzgeroth G; Erben P; Popp H; Walz C; Hochhaus A; Roche-Lestienne C; Preudhomme C; Solomon E; Apperley J; Rondoni M; Ottaviani E; Martinelli G; Brito-Babapulle F; Saglio G; Hehlmann R; Cross NC; Reiter A; Grimwade D Blood; 2007 Jun; 109(11):4635-40. PubMed ID: 17299092 [TBL] [Abstract][Full Text] [Related]
82. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Chung KF; Hew M; Score J; Jones AV; Reiter A; Cross NC; Bain BJ Eur Respir J; 2006 Jan; 27(1):230-2. PubMed ID: 16387954 [TBL] [Abstract][Full Text] [Related]
83. Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. Ibata M; Iwasaki J; Fujioka Y; Nakagawa K; Darmanin S; Onozawa M; Hashimoto D; Ohba Y; Hatakeyama S; Teshima T; Kondo T Cancer Sci; 2017 Feb; 108(2):200-207. PubMed ID: 27960034 [TBL] [Abstract][Full Text] [Related]
84. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Cools J; Stover EH; Gilliland DG Methods Mol Med; 2006; 125():177-87. PubMed ID: 16502585 [TBL] [Abstract][Full Text] [Related]
85. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197 [TBL] [Abstract][Full Text] [Related]
86. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib]. Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284 [TBL] [Abstract][Full Text] [Related]
87. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Voulgarelis M; Moutsopoulos HM Medicine (Baltimore); 2007 Nov; 86(6):344-354. PubMed ID: 18004179 [TBL] [Abstract][Full Text] [Related]
88. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Borbényi Z Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304 [TBL] [Abstract][Full Text] [Related]
89. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy]. Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920 [No Abstract] [Full Text] [Related]